PARTNERS WITH UNH
First hire of UNH graduate celebrated
Contact: Mary Peterson
University Relations and UNH Foundation
June 24, 2004
DURHAM, N.H. -- University of New Hampshire administrators
and senior executive officers of Bentley Pharmaceuticals, Inc.
recently to celebrate Bentley's first hire of a UNH graduate and
lay the groundwork for future collaboration. Materials scientist
Zhengmao Li, Ph.D. '04 has been named manager of protein/peptide
delivery programs for the Exeter, N.H.-based company. "It's
a perfect fit," said Robert J. Gyurik, Bentley's vice president
of pharmaceutical development. "Zhengmao came to us fully
formed, and he's already translating our needs into new technology."
|From left to right, UNH President Ann Weaver
Hart, Zhengmao Li '04, and Bentley Pharmaceuticals President
James Murphy in Bentley's Exeter, N.H. laboratory.
As a graduate student at UNH, Li studied intranasal
insulin delivery under materials science Professor Yvon Durant—a project jointly
sponsored by the university, the New Hampshire Industrial Research
Center, and Bentley. "At UNH, students can build life-long
relationships with faculty who are conducting cutting-edge research," Li
We are delighted to celebrate Zhengmao's new position and look
forward to our ongoing partnership with Bentley," UNH President
Ann Weaver Hart said. "The university is committed to the
production of knowledge that addresses scientific needs in today's
world, and one way we fulfill this mission is through deep and
reciprocal relationships such as the one we recognize with Bentley."
As a New Hampshire company, we appreciate that our state university
can provide us with outstanding resources," said James R.
Murphy, chairman, president, and CEO for Bentley. The company
recently collaborated with UNH testing an intranasal spray as
form of insulin delivery.
A specialty pharmaceutical company focused on advanced drug delivery
technologies and pharmaceutical products, Bentley manufactures
and markets a growing portfolio of generic and branded pharmaceuticals
in Europe through its subsidiaries in Spain. In May, the company,
which has 326 employees in Europe and the U.S., began trading
on the New York Stock Exchange under the ticker symbol "BNT."
At UNH, we don't create barriers between our research groups," said
John Aber, vice president for research and public service. "Our
relationship with Bentley is an excellent example of the kind
of public-private partnership that UNH is creating. Our interaction
with Bentley brings new resources and energy to the process of
discovery that is a core UNH mission."
Bentley is the largest pharmaceutical company in New Hampshire," said
Arthur Greenberg, dean of the College of Engineering and Physical
Sciences, "and we look forward to collaborations that will
partner the resources of the university, state-of-the-art instrumentation,
materials science, organic synthesis, and computational chemistry
with this forward-looking company."
The biggest thing we can offer Bentley is the collaborations we
provide," added UNH's William Trumble, dean of the College
of Life Sciences and Agriculture. "We have an environment
in which we can pull in areas of expertise—for example, our
genomics center, the use of robotics to develop chip technology,
immunology, and endochrinomics." The college's Center to
Advance Molecular Interaction Science (CAMIS) serves the pharmaceutical,
biotechnology and materials science industries through the development
of tools and techniques to characterize and control the interaction
of biological molecules
Members of the university party included President Ann Weaver Hart;
John Aber, vice president for research and public service; Arthur
Greenberg, dean, College of Engineering and Physical Science; William
Trumble, dean, College of Life Sciences and Agriculture; Yvon Durant,
professor, materials science; Jerome Claverie, professor, materials
science; Jennifer Goldberg, associate director of major gifts,
UNH Foundation, Inc.; and graduate student Floraine Collette, who
is involved with the research programs funded by Bentley Pharmaceuticals.
The Bentley group included James R. Murphy, chairman, president,
and CEO; Robert J. Gyurik, vice president, pharmaceutical development;
James Hand, vice president, business development and licensing;
Michael D. Price, chief financial officer; Paul Fitzgibbons, director,
program and project management; Zhengmao Li, manager, protein/peptide
development program; Carl Reppucci, manager, formulation science;
and Ivo Velazco, manager, product development.
A photo is available
for download at: http://www.unh.edu/news/img/bentley.jpg